JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263398

Human TRAPPC2L knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

TRAPPC2L KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

View Alternative Names

HSPC176, Trafficking protein particle complex 2 like

1 Images
Sanger Sequencing - Human TRAPPC2L knockout HEK-293T cell lysate (AB263398)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRAPPC2L knockout HEK-293T cell lysate (AB263398)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263398-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human TRAPPC2L knockout HEK293T cell lysate", "number":"AB263398-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB263398-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
TRAPPC2L
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRAPPC2L also known as trafficking protein particle complex 2L is a protein approximately 52 kDa in mass. It plays a role in vesicle-mediated transport processes. TRAPPC2L is widely expressed in various tissues but shows higher expression in the adrenal gland and testis. Its mechanical function involves the regulation of intracellular protein trafficking which is important for transporting proteins to their proper destinations within cells.
Biological function summary

This protein is a component of the TRAPP complex a multi-subunit protein assembly involved in the tethering of transport vesicles before fusion with their target membranes. TRAPPC2L contributes to the function and structural integrity of this complex which is essential for maintaining cellular organization and exchanging materials between different cellular compartments. This involvement implies that TRAPPC2L plays a significant part in cellular logistics and maintenance of homeostasis.

Pathways

TRAPPC2L engages in the secretory pathway interfacing with the SNARE proteins necessary for vesicle fusion. This protein also links to the Ypt/Rab GTPases pathway which regulates vesicular transport and budding processes. Through these interactions TRAPPC2L associates with proteins like TRAPPC2 and TRAPPC3 enhancing vesicle tethering and trafficking dynamics.

TRAPPC2L shows associations with medical conditions such as congenital disorders of glycosylation and nephrotic syndrome. Deficient or dysfunctional TRAPPC2L can disrupt vesicle transport pathways leading to cellular dysfunction and disease. The pathways connected to TRAPPC2L can also involve other proteins like TRAPPC2 and TRAPPC9 which contribute to the pathology through their interconnected roles in similar transport processes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com